The present study introduces a robust biomarker, namely RPL22L1, which exhibits elevated expression in LUAD patients, aligning with its increased expression in PRAD, HCC, CRC, KIRC, and OC [7, 9–13]. Here, RPL22L1 is linked to prostate adenocarcinoma.